SAM #NOI-PCA-NIDA-09054

Pharmacogenomic Analysis and Whole Genome Sequencing Services for STAR-B Clinical Trial (Sole Source to Novogene)

This opportunity is for specialized pharmacogenomic analysis services supporting the STAR-B clinical trial of semaglutide for alcohol use disorder, managed by the National Institute on Drug Abuse (NIDA). - Sole source award to Novogene Corporation, Inc. for Human Whole Genome Sequencing services - Includes DNA extraction, quality control, genome-wide genotyping/sequencing, bioinformatics processing, and data delivery - Ensures methodological consistency with the STAR-T trial at Oklahoma State University, which also uses Novogene - Comprehensive laboratory and bioinformatics services required - Receive and process biospecimens - Perform DNA extraction and quality control - Conduct genome-wide genotyping/sequencing - Generate and deliver raw and processed genomic data files and reports - Maintain chain-of-custody and sample tracking - No hardware, part numbers, or specific quantities are specified - Period of performance is 12 months from award - Opportunity is focused on scientific services, not products - No competitive solicitation; sole source justification provided

Description

Please see the attached Notice of Intent titled NOI-PCA-NIDA-09054 and Statement of Work. 

View original listing